Longeveron (NASDAQ:LGVN) stock continues to rally on Thursday as investors celebrate positive trial news from the clinical-stage biotechnology company.
The big news that boosted shares of LGVN stock higher was investigator data from a Phase 2 trial of Lomocel-B. This is the company’s treatment candidate for patients suffering from hypoplastic left heart syndrome (HLHS).
The Phase 2 trial of Lomocel-B is still ongoing and the investigator meeting was positive. That’s a win for the company and investors in LGVN stock. There’s also demand for its product, as HLHS is often fatal and requires many surgeries.
How This Affects LGVN Stock
The initial announcement of this investigator data for the clinical trial saw shares of LGVN stock rally 120% higher yesterday. It did so with heavy trading as some 65.3 million shares changed hands. That’s well above its daily average of 3.3 million shares.
LGVN stock is still rallying on Thursday with the company’s shares up 45.9% this morning. This comes with more than 17.5 million shares traded as of this writing. It’s possible this could see the stock close out Thursday with another rally under its belt.
Investors looking for more of the most recent stock market stories are in luck!
We have all of the hottest stock market stories available to investors on Thursday! Among that is what has shares of Neo-Concept (NASDAQ:NCI) stock up, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the links below!
More Stock Market News for Thursday
- Why Is Neo-Concept (NCI) Stock Up 61% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
- Trade of the Day: Place a Contrarian Bet on Dave & Buster’s (PLAY) Stock
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
